Biotricity Inc. reported third‑quarter fiscal 2026 results that included a $4.0 million revenue increase of 10.2% year‑over‑year, a net operating income of $0.3 million, and a net loss that narrowed to $1.1 million, or $0.042 per share, from a $1.3 million loss ($0.054 per share) in the same quarter last year.
Revenue growth was driven by a 10.2% rise in recurring technology fees, which now account for 91.2% of total revenue. The company’s subscription‑based remote cardiac monitoring model continued to expand, with the recurring fee mix shifting toward higher‑margin services and a modest increase in new customer acquisition. Compared with Q2 FY26, revenue grew from $3.9 million to $4.0 million, while the net loss improved from $0.77 million to $1.1 million, reflecting stronger top‑line momentum and tighter cost control.
Gross margin expanded to 81.5% in Q3 FY26, up from 76.4% in the prior year quarter. The improvement is largely attributable to a higher proportion of recurring revenue and operational efficiencies gained through the company’s proprietary AI‑driven automation, which reduced monitoring and cloud‑hosting costs. The margin lift demonstrates that the platform’s high‑margin software model is scaling effectively as revenue grows.
The company’s third consecutive quarter of positive EBITDA underscores its ability to generate predictable recurring cash flow. Net operating income of $0.3 million, combined with a narrowed net loss, signals that Biotricity is managing its cost base while scaling its subscription business. These metrics provide a stronger foundation for future product development and market expansion without the need for additional dilution.
Management highlighted the company’s progress toward FDA clearance for its cardiac AI model and its plans to expand into international markets. CEO Dr. Waqaas Al‑Siddiq emphasized that the firm expects to continue increasing top‑line revenue, shift to profitability, and post another growth year, while CFO John Ayanoglou noted the global relevance of the technology, positioning Biotricity to capture a leading share of the chronic care market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.